|
Characteristic
|
Omeprazole group (n = 303)
|
Pantoprazole group (n = 304)
|
P value
|
|---|
|
Stent thrombosis [n (%)]
|
0
|
0
|
—
|
|
MACEs [n (%)]
|
8 (2.6)
|
7 (2.3)
|
0.80
|
|
Cardiac death
|
1 (0.3)
|
0
|
0.50
|
|
Myocardial infarction
|
0
|
0
|
—
|
|
Ischemic symptoms driven target vessel revascularization
|
3 (1.0)
|
1 (0.3)
|
0.37
|
|
Non-target vessel revascularization
|
6 (2.0)
|
6 (2.0)
|
1.00
|
|
Recurrent angina [n (%)]
|
30 (9.9)
|
24 (7.9)
|
0.40
|
|
All-cause death [n (%)]
|
1 (0.3)a
|
1 (0.3)b
|
1.00
|
|
TIMI bleeding evens [n (%)]
|
15 (5.0)
|
19 (6.3)
|
0.60
|
|
Major
|
0
|
1 (0.3)
|
1.00
|
|
Moderate
|
0
|
3 (1.0)
|
0.25
|
|
Minor
|
16 (5.3)
|
14 (4.6)
|
0.71
|
|
Stroke [n (%)]
|
1 (0.3)
|
0
|
0.50
|
|
Adverse drug reactions [n (%)]
|
17 (5.6)
|
19 (6.3)
|
0.86
|
|
AEs [n (%)]
|
50 (16.5)
|
44 (14.5)
|
0.50
|
-
aOne patient died due to lung cancer in the omeprazole group
-
bOne patient died due to acute brainstem hemorrhage in the pantoprazole group
